Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
07/2011
07/12/2011CA2481767C Severe sepsis preventive therapeutic agent
07/12/2011CA2470721C Superoxide dismutase mimics for the treatment of ocular disorders and diseases
07/12/2011CA2463616C Affinity enhancement agents
07/12/2011CA2461202C Lactam-containing compounds and derivatives thereof as factor xa inhibitors
07/12/2011CA2449150C Tricyclic compounds useful as angiotensin ii agonists
07/12/2011CA2445341C Anthranilamides, process for their preparation, their use as antiarrhythmics, and pharmaceutical preparations thereof
07/12/2011CA2435611C Alpha-amino-n-hydroxy-acetamide derivatives
07/12/2011CA2397347C Factor vii or viia-like molecules
07/12/2011CA2393312C Aminobenzophenones as inhibitors of il-1.beta. and tnf-.alpha.
07/12/2011CA2389685C Novel heterocyclic compounds and their use as medicaments
07/12/2011CA2376375C Method and composition for inhibiting cardiovascular cell proliferation
07/12/2011CA2352286C Intracellular targeted delivery of compounds by 70 kd heat shock protein
07/12/2011CA2341336C Elongase genes and uses thereof
07/12/2011CA2312274C Isolated dna encoding human h3 histamine receptor
07/12/2011CA2302874C Jnk3 modulators and methods of use
07/12/2011CA2291514C Methods for evaluating tissue morphogenesis and activity
07/12/2011CA2162262C Methods for treating muscle diseases and disorders
07/07/2011WO2011082328A1 Methods for performing a coronary artery bypass graft procedure
07/07/2011WO2011082324A1 Methods for the prevention or treatment of vessel occlusion injury
07/07/2011WO2011082245A2 Metalloenzyme inhibitor compounds
07/07/2011WO2011081970A2 MOLECULES RELATED hERG Ion CHANNELS AND THE USE THEREOF
07/07/2011WO2011081523A1 Interferon analogs
07/07/2011WO2011081173A1 Tetracyclic compound
07/07/2011WO2011081118A1 Pharmaceutical composition for oral administration
07/07/2011WO2011081117A1 Solid pharmaceutical composition for oral administration
07/07/2011WO2011080755A1 Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
07/07/2011WO2011080269A2 Pharmaceutical preparations comprising a cos releasing compound
07/07/2011WO2011080220A1 An agent for stimulating the expression of loxl
07/07/2011WO2011079410A1 Medicinal composition including sunflower extract, preparative method and use thereof
07/07/2011WO2011008028A9 Functional drinking water for improving blood circulation, and method for preparing same
07/07/2011WO2010151004A9 Injectable composition containing hydroxychloroquine for local administration for treating hemorrhoids
07/07/2011US20110166548 Drug releasing coatings for medical devices
07/07/2011US20110166320 Somatostatin analogues
07/07/2011US20110166233 Compounds for the treatment of metabolic disorders
07/07/2011US20110166228 Composition
07/07/2011US20110166224 Diacylglycerol rich fats, oils and functional foods
07/07/2011US20110166221 Use of dronedarone for the preparation of a medicament for use in the prevention of cardioversion
07/07/2011US20110166220 Dronedarone for the prevention of permanent atrial fibrillation
07/07/2011US20110166218 Methods for micronization of hydrophobic drugs
07/07/2011US20110166181 Guanidine compounds as anesthetics and for treatment of nervous system disorders
07/07/2011US20110166178 Methods for treating anemia using inhibitors of hypoxia-inducible factor (HIF) hydroxylase
07/07/2011US20110166176 Compounds and compositions as modulators of gpr119 activity
07/07/2011US20110166175 7-azaindole derivatives
07/07/2011US20110166173 3,5-disubstututed 1h-pyrrolo [2,3-b] pyridines as jnk inhibitors
07/07/2011US20110166163 Substituted furopyrimidines and use thereof
07/07/2011US20110166161 Heterocyclic carboxamide compounds
07/07/2011US20110166152 Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
07/07/2011US20110166145 Stabilization of hypoxia inducible factor (HIF) alpha
07/07/2011US20110166142 2-substituted isoflavonoid compounds, medicaments and uses
07/07/2011US20110166140 Novel sulphonylpyrroles
07/07/2011US20110166136 Calcium Ion Channel Modulators & Uses Thereof
07/07/2011US20110166125 Substituted amides, manufacturing and use thereof as medicaments
07/07/2011US20110166124 Tricyclic spirocycle derivatives and methods of use
07/07/2011US20110166121 Fused heterocyclic compound
07/07/2011US20110166104 Boron-containing small molecules
07/07/2011US20110166103 Boron-containing small molecules
07/07/2011US20110166097 Taxane compounds for treating eye disease
07/07/2011US20110166093 Use of adenosine receptor agonists in therapy
07/07/2011US20110166075 Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment
07/07/2011US20110166073 Anti-hypertensive agent
07/07/2011US20110166068 Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
07/07/2011US20110166067 Methods for inhibition of scarring
07/07/2011US20110166065 Modulation of glucose-6-phosphatase translocase expression
07/07/2011US20110165274 Xanthine Oxidase Inhibitor And Uric Acid Production Inhibitor
07/07/2011US20110165256 Compositions and methods for treatment of hyperplasia
07/07/2011US20110165249 Pharmaceutical solid preparation
07/07/2011US20110165240 Galenical formulations of organic compounds
07/07/2011US20110165239 Pharmaceutical compositions of atorvastatin
07/07/2011US20110165235 Directly pressed aliskiren tablets
07/07/2011US20110165233 Stability additives for dry dha dosage forms
07/07/2011US20110165216 Hydrogen Sulfide Generating Polymers
07/07/2011US20110165186 Novel pyridine alkaloids, preparation process thereof, and the uses of the pyridine alkaloids
07/07/2011US20110165176 Aldosterone induced vascular elastin production
07/07/2011US20110165173 Therapeutic agent and detection reagent for arteriosclerotic disease which targets for salusin
07/07/2011US20110165166 Lsr receptor, its activity, its cloning, and its applications to the diagnosis, prevention and/or treatment of obesity and related risks or complications
07/07/2011US20110165138 Protocols for treating and preventing obesity and complications arising therefrom
07/07/2011US20110165135 Lactobacillus helveticus strains for producing hypotensive peptides
07/07/2011US20110165128 Homing in mesenchymal stem cells
07/07/2011US20110165096 Ficus Extracts Having Angiogenesis Ihibiting Activity And Methods Of Isolating And using The Same
07/07/2011US20110165095 Composition and method for the inhibition of postoperative adhesions severity
07/07/2011US20110165066 Interleukin-13 binding proteins
07/07/2011US20110165063 Il-1 binding proteins
07/07/2011DE102009028929A1 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung Heterocyclic-substituted 2-acetamido-5-aryl-1,2,4-triazolones and their use
07/07/2011CA2786280A1 Methods for the prevention or treatment of vessel occlusion injury
07/07/2011CA2786090A1 Interferon analogs
07/07/2011CA2786066A1 Methods for performing a coronary artery bypass graft procedure
07/07/2011CA2785898A1 Metalloenzyme inhibitor compounds
07/06/2011EP2341348A1 Methods for detecting cross beta structure comprising proteins with crossbeta structure binding compounds.
07/06/2011EP2341143A1 OX2 receptor homolog
07/06/2011EP2341141A2 Recombinant platelet collagen receptor glycoprotein VI , antibodies and their pharmaceutical use
07/06/2011EP2341138A1 FUSION PROTEIN COMPOSED OF MATRIX METALLOPROTEINASE-2 INHIBITOR PEPTIDE DERIVED FROM AMYLOID-beta PRECURSOR PROTEIN AND TISSUE INHIBITOR OF METALLOPROTEINASE-2
07/06/2011EP2341068A1 A method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
07/06/2011EP2341052A1 Ring-fused morpholine derivative having pi3k-inhibiting activity
07/06/2011EP2341049A1 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as PTPASE 1B inhibitors
07/06/2011EP2341048A1 Thiazolium salt compound and the use of treating the protein aging disease
07/06/2011EP2341045A1 [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid (acyloxy)alkyl or ((alkoxycarbonyl)oxy)alkyl ester as SPLA2 inhibitor
07/06/2011EP2340843A1 Methods and compositions to treat myocardial conditions
07/06/2011EP2340828A1 Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor
07/06/2011EP2340822A1 Acylated 4-amidino and 4-guanidinobenzylamines for inhibiting plasma kallikreins
07/06/2011EP2340821A1 Prophylactic/ameliorating agent for adult diseases comprising 5-aminolevulinic acid, derivative of 5-aminolevulinic acid, or salt of 5-aminolevulinic acid or the derivative of 5-aminolevulinic acid as active ingredient